Free Newsletter
Scientists report Alzheimer's vaccine success
Scientists at Japan's National Institute for Longevity Sciences are planning to push an oral Alzheimer's vaccine into clinical trials after reporting that the therapy worked in mice. The institute's director, Takeshi Tabira, says that it may be that the therapy only works at the early stage of development in humans. But when tested in mice, the researchers found that the vaccine reduced beta amyloid in the animals genetically modified to develop Alzheimer's and improved their brain function. Mental function returned to near normal levels three months after being treated with a vaccine that spurred their immune system to attack amyloid proteins. No side effects such as bleeding or inflammation was observed. One in five people over the age of 80 suffer from dementia, and most of them have Alzheimer's.
- read this report on the research from The Guardian
Related Articles:
Alzheimer's patch used to deliver vaccine to mice. Report
Researchers tout results for new Alzheimer's test. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
